Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Calcium Citrates
2. Citrate, Calcium
3. Citrates, Calcium
1. 813-94-5
2. Tricalcium Dicitrate
3. Tricalcium Citrate
4. Acicontral
5. Calcitrate
6. Calcium Citrate, Tribasic
7. Calcium Citrate Anhydrous
8. Calcium 2-hydroxy-1,2,3-propanetricarboxylate (3:2)
9. Tricalcium Citrate Tetrahydrate
10. Ins No.333(iii)
11. Ins-333(iii)
12. 2-hydroxy-1,2,3-propanetricarboxylic Acid Calcium Salt (2:3)
13. 1,2,3-propanetricarboxylic Acid, 2-hydroxy-, Calcium Salt (2:3)
14. 86117bwo7p
15. E-333(iii)
16. Tricalcium;2-hydroxypropane-1,2,3-tricarboxylate
17. Calcimax
18. Citrical
19. Calcium (as Citrate)
20. Calcium 2-hydroxypropane-1,2,3-tricarboxylate (3:2)
21. Tribasic Calcium Citrate
22. Calcium Citrate [usan]
23. 7693-13-2
24. Hsdb 5756
25. Citric Acid, Calcium Salt (2:3)
26. Einecs 212-391-7
27. Calciumcitrate
28. Unii-86117bwo7p
29. Lime Citrate
30. Calcium Citrate Powder
31. Calcium Citrate Tribasic
32. Calcium Citrate, Anhydrous
33. Ec 212-391-7
34. Calcium Citrate Usp, Fcc
35. Tricalcium Bis(citric Acid)
36. Calcium Citrate [mi]
37. Calcium Citrate [hsdb]
38. Chembl2106123
39. Dtxsid7061148
40. Calcium Citrate [who-dd]
41. Citric Acid Calcium Salt (2:3)
42. Chebi:190513
43. Mfcd00078618
44. Akos015839590
45. Db11093
46. Calcium Citrate Malate Glycinate 21% 40m
47. Q420280
48. Calcium Citrate Malate Carbonate 23%, Coarse Granu
49. J-509604
50. Calcium 2-hydroxypropane-1,2,3-tricarboxylate (3/2)
51. Tricalcium Bis(2-hydroxypropane-1,2,3-tricarboxylic Acid)
Molecular Weight | 498.4 g/mol |
---|---|
Molecular Formula | C12H10Ca3O14 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 14 |
Rotatable Bond Count | 4 |
Exact Mass | 497.8948275 g/mol |
Monoisotopic Mass | 497.8948275 g/mol |
Topological Polar Surface Area | 281 Ų |
Heavy Atom Count | 29 |
Formal Charge | 0 |
Complexity | 211 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 5 |
For use as an over the counter calcium supplement.
FDA Label
Increases plasma calcium levels leading to a decrease in calcium flux and increase in calcium deposition into bone
Food Additives
Substances used in the processing or storage of foods or animal feed including ANTIOXIDANTS; FOOD PRESERVATIVES; FOOD COLORING AGENTS; FLAVORING AGENTS; ANTI-INFECTIVE AGENTS; EXCIPIENTS and other similarly used substances. Many of the same substances are used as PHARMACEUTIC AIDS. (See all compounds classified as Food Additives.)
A - Alimentary tract and metabolism
A12 - Mineral supplements
A12A - Calcium
A12AA - Calcium
A12AA13 - Calcium citrate
Absorption
The percentage of calcium absorbed varies inversely with intake. Tmax of about 3.5-5h varying with formulation.
Route of Elimination
Cleared via the kidneys but largely reabsorbed (98-99%) under normal conditions.
Calcium citrate increases plasma calcium levels. This reduces calcium flux from osteocyte activity by reducing the secretion of parathyroid hormone (PTH). Calcium does this by stimulating a G-protein coupled calcium receptor on the surface of parathyroid cells. The reduction in calcium flux increases the amount of calcium deposited in bone resulting in an increase in bone mineral density. The reduction in PTH secretion also reduces the amount of vitamin D metabolized to its active form, calcidiol. Since calcidiol increases the expression of calcium dependent ATPases and transient receptor potential cation channel subfamily V member 6 (TRPV6) both of which are involved in calcium uptake from the gut, a reduction in calcidiol results in less calcium absorption. Additionally, TRPV5, the channel responsible for calcium reabsorption in the kidney, is downregulated when PTH secretion is reduced thus increasing calcium excretion via the kidneys. Another hormone, calitonin, is likely involved in the reduction of bone resorption during periods of high plasma calcium.
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
51
PharmaCompass offers a list of Calcium Citrate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Calcium Citrate manufacturer or Calcium Citrate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Calcium Citrate manufacturer or Calcium Citrate supplier.
PharmaCompass also assists you with knowing the Calcium Citrate API Price utilized in the formulation of products. Calcium Citrate API Price is not always fixed or binding as the Calcium Citrate Price is obtained through a variety of data sources. The Calcium Citrate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A E333 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of E333, including repackagers and relabelers. The FDA regulates E333 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. E333 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of E333 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A E333 supplier is an individual or a company that provides E333 active pharmaceutical ingredient (API) or E333 finished formulations upon request. The E333 suppliers may include E333 API manufacturers, exporters, distributors and traders.
click here to find a list of E333 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A E333 DMF (Drug Master File) is a document detailing the whole manufacturing process of E333 active pharmaceutical ingredient (API) in detail. Different forms of E333 DMFs exist exist since differing nations have different regulations, such as E333 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A E333 DMF submitted to regulatory agencies in the US is known as a USDMF. E333 USDMF includes data on E333's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The E333 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of E333 suppliers with USDMF on PharmaCompass.
A E333 written confirmation (E333 WC) is an official document issued by a regulatory agency to a E333 manufacturer, verifying that the manufacturing facility of a E333 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting E333 APIs or E333 finished pharmaceutical products to another nation, regulatory agencies frequently require a E333 WC (written confirmation) as part of the regulatory process.
click here to find a list of E333 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing E333 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for E333 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture E333 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain E333 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a E333 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of E333 suppliers with NDC on PharmaCompass.
E333 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of E333 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right E333 GMP manufacturer or E333 GMP API supplier for your needs.
A E333 CoA (Certificate of Analysis) is a formal document that attests to E333's compliance with E333 specifications and serves as a tool for batch-level quality control.
E333 CoA mostly includes findings from lab analyses of a specific batch. For each E333 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
E333 may be tested according to a variety of international standards, such as European Pharmacopoeia (E333 EP), E333 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (E333 USP).